On 10 June 2010, orphan designation (EU/3/10/732) was granted by the European Commission to Nexus Oncology Ltd, United Kingdom, for entinostat for the treatment of Hodgkin's lymphoma.
Treatment of Hodgkin's lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
|September 2023||The sponsorship was transferred from Propharma Group The Netherlands B.V., Netherlands, to Syndax Europe B.V., Netherlands|
|April 2022||The sponsorship was transferred to Propharma Group The Netherlands B.V., Netherlands|
|June 2021||The sponsor's address was updated.|
|February 2019||The sponsorship was transferred to Southwood Research Limited The Netherlands.|
|April 2015||The sponsorship was transferred to Syndax Limited, United Kingdom|
|February 2013||Nexus Oncology Ltd changed name to Ockham Europe Limited.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: